GIPC1 and retinoblastoma: Incorporating LRP2, CUBN, Caveolin-1, GIPC1, and DAB2IP into biomarker-driven clinical trial design could enhance risk stratification in uveal melanoma and RB and support the development of prognostic signatures that distinguish aggressive from indolent disease.